Sign inJoin waitlistJoin the waitlist

Walter Stadler

Named Section Chief of Hematology/Oncology at the University of Chicago Medicine · University of Chicago Medical Center

Credentials: · · · ·

History

hematology/oncology at the University of Chicago Medicine Section · University of Chicago Medical Center
Present
City of Hope National Medical Center
Present

Hematology and Medical Oncology
University of Chicago Medical Center
1991–1994
Michael Reese Hospital and Medical Center
1988–1991
Yale Univ Sch of Med
1984–1988

Research

Sorafenib in advanced clear-cell renal-cell carcinoma
New England Journal of Medicine · 2007 · 3,998 citations
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Journal of Clinical Oncology · 2016 · 1,422 citations
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
Nature Medicine · 2018 · 1,024 citations

NV
Nicholas Vogelzang
61 papers
Mark Ratain
41 papers
Brian Rini
29 papers · 7 as a fellow
Everett Vokes
24 papers
Russell Szmulewitz
22 papers · 2 as a fellow
Eric Small
21 papers
Peter O'Donnell
20 papers · 2 as a fellow
CR
Christopher Ryan
18 papers · 2 as a fellow
Daniel George
15 papers
Toni Choueiri
15 papers
Maha Hussain
14 papers
AD
Apurva Desai
13 papers · 3 as a fellow

Grants

Experimental Therapeutics: Clinical Trials Network with Phase I Emphasis
National Cancer Institute · UM1
PI · $476.5K · University of Chicago
2014–2017
Early Therapeutics Development with Phase Ii Emphasis
National Cancer Institute · N01
Contact PI · $4M · University of Chicago
2011–2016
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $559.9K · University of Chicago
2008–2013
Early Therapeutics Development with Phase II Emphasis
National Cancer Institute · N01
Contact PI · $856.7K · University of Chicago
2006–2011

Clinical trials

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
Principal investigator · Terminated · Phase 1
University of Chicago
2023–2024
Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
Principal investigator · Terminated · Phase 1, Phase 2
University of Chicago
2018–2020
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
Principal investigator · Terminated
University of Chicago
2012–2015
Saracatinib in Treating Patients With Prostate Cancer
Principal investigator · Terminated · Phase 2
National Cancer Institute (NCI)
2010–2013